Literature DB >> 15026085

Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.

Jennifer H Gutzman1, Kristin K Miller, Linda A Schuler.   

Abstract

Prolactin (PRL) and estrogen act synergistically to increase mammary gland growth, development, and differentiation. Based on their roles in the normal gland, these hormones have been studied to determine their interactions in the development and progression of breast cancer. However, most studies have evaluated only endocrine PRL and did not take into account the recent discovery that PRL is synthesized by human mammary cells, permitting autocrine/paracrine activity. To examine the effects of this endogenous PRL, we engineered MCF7 cells to inducibly overexpress human prolactin (hPRL). Using this Tet-On MCF7hPRL cell line, we studied effects on cell growth, PRLR, ER alpha, and PgR levels, and estrogen target genes. Induced endogenous hPRL, but not exogenous hPRL, increased ER alpha levels as well as estrogen responsiveness in these cells, suggesting that effects on breast cancer development and progression by estrogen may be amplified by cross-regulation of ER alpha levels by endogenous hPRL. The long PRLR isoform was also upregulated by endogenous, but not exogenous PRL. This model will allow investigation of endogenous hPRL in mammary epithelial cells and will enable further dissection of PRL effects on other hormone signaling pathways to determine the role of PRL in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026085     DOI: 10.1016/j.jsbmb.2003.10.008

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  41 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

3.  Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.

Authors:  Anton Pottegård; Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

Review 4.  Nongenomic signaling pathways of estrogen toxicity.

Authors:  Cheryl S Watson; Yow-Jiun Jeng; Mikhail Y Kochukov
Journal:  Toxicol Sci       Date:  2009-12-02       Impact factor: 4.849

Review 5.  Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Authors:  Katherine A Leehy; Thu H Truong; Laura J Mauro; Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2017-04-23       Impact factor: 4.292

6.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Authors:  Jennifer H Gutzman; Sarah E Nikolai; Debra E Rugowski; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2005-03-03

8.  Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells.

Authors:  Juu-Chin Lu; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2005-08-15       Impact factor: 5.157

Review 9.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

10.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.